Gene expression and single nucleotide polymorphism of ATP7B are associated with platinum-based chemotherapy response in non-small cell lung cancer patients

Abstract

Objectives: Platinum-based chemotherapy is first-line treatment for non-small cell lung cancer (NSCLC) patients. The efficacy is limited by drug resistance. Recent studies suggest that ATP7B, a copper efflux transporter, may be involved in platinum resistance. However, the clinical significance of ATP7B expression in NSCLC is controversial. Moreover, the effects of single nucleotide polymorphisms (SNPs) in ATP7B gene on the response to platinum-based chemotherapy are scarcely understood. The aim of our study is to evaluate the clinical value of ATP7B in NSCLC patients and explore the interrelationships between ATP7B SNPs and protein expression, and their association with chemotherapy response.Materials and Methods: A total of 247 NSCLC patients were recruited in this study. Among them, 158 patients who received platinum-based chemotherapy were used to explore the interrelationships between ATP7B SNPs, protein expression and chemotherapy response, while 89 patients who underwent surgical resection were used to further investigate the association between ATP7B SNPs and expression level. We genotyped 15 SNPs of ATP7B by Sequenom MassARRAY and determined ATP7B protein levels by immunohistochemistry.Results: Patients with ATP7B-negative tumors had improved chemotherapeutic response (p=0.025) and better overall survival (p=0.044) compared with the patients with ATP7B-positive tumors. The multivariate Cox regression analysis revealed that ATP7B expression was an independent prognostic factor (HR=0.639, 95%CI=0.424-0.962, p=0.032). Moreover, we found that the rs9526814 GG genotype was significantly associated with favorable response to platinum-based chemotherapy when compared with TT+TG genotypes (OR=0.362, 95CI%=0.140-0.935, p=0.036). Mechanistically, rs9526814 GG genotype showed a strong trend towards reduced expression level of ATP7B compared with the TT+TG genotypes (p= 0.048).Conclusion: Our findings indicate that ATP7B rs9526814 may contribute to platinum resistance by influencing ATP7B gene expression and can be used as a potential biomarker to predict the sensitivity of platinum-based chemotherapy in NSCLC patients.

Copper ions are novel therapeutic agents for uterine leiomyosarcoma

“…ATP7B is expressed in the normal liver, kidney, and placenta tissues and in platinum-resistant ovarian and endometrial cancer and colorectal, lung, and gastric cancers. 24,[33][34][35][36][37] In this study, pretreatment with Cu and cisplatin was used to determine which compound was ajog.org GYNECOLOGY Original Research effluxed by ATP7B. The changes in localization after cisplatin or CuSO 4 exposure in SK-LMS-1 cells, investigated using immunofluorescence analysis, were consistent with those reported in previous studies.…”

Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis

“…The majority of patients are diagnosed with metastatic diseases at the initial visit, which highlights the importance of effective systemic therapies (3). The traditional therapy is chemotherapy, and certain gene expression patterns (4,5) and liquid biomarkers (6,7) serve as predictors of chemotherapy outcomes. Targeted therapy with small molecule tyrosine…”

<p>The role of PEG3 in the occurrence and prognosis of colon cancer</p>

“…Immunohistochemistry was performed as previously described 20. Paraffin embedded tissue sections were cut to 4 μm thick and blocked with endogenous peroxidase.…”